Shots:

• NeuExcell is eligible to receive $190M up front- license fees- R&D- and sales milestones along with royalties
• Spark gets the option to license the global exclusive rights of NeuExcell's HD program & will receive access to NeuExcell's neuro-regenerative gene therapy platform & capabilities. NeuExcell is developing AAVs based neuroregenerative gene therapy to regenerate functional new neurons at the site of the neurodegeneration
• The focus of the collaboration is to develop a safe and effective treatment for patients with HD by using NeuExcell's neuroregenerative gene therapy platform

| Ref: PR Newswire | Image: PR Newswire